M Schreurs1, T H van Dijk, A Gerding, R Havinga, D-J Reijngoud, F Kuipers. 1. Department of Pediatrics, Center for Liver Digestive and Metabolic Diseases, University Medical Center Groningen, University of Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands. m.schreurs@med.umcg.nl
Abstract
AIM: Inhibition of the acetyl-CoA carboxylase (ACC) system, consisting of the isozymes ACC1 and ACC2, may be beneficial for treatment of insulin resistance and/or obesity by interfering with de novo lipogenesis and beta-oxidation. We have evaluated effects of pharmacological inhibition of ACC by soraphen (SP) on high fat (HF) diet-induced insulin resistance in mice. METHOD: Male C57Bl6/J mice were fed control chow, a HF diet or a HF diet supplemented with SP (50 or 100 mg/kg/day). RESULTS: Body weight gain and total body fat content of SP-treated animals were significantly reduced compared with HF-fed mice. Fractional synthesis of palmitate was significantly reduced in mice treated with SP, indicative for ACC1 inhibition. Plasma beta-hydroxybutyrate levels were significantly elevated by SP, reflecting simultaneous inhibition of ACC2 activity. Mice treated with SP showed improved peripheral insulin sensitivity, as assessed by hyperinsulinaemic euglycaemic clamps. CONCLUSION: Pharmacological inhibition of the ACC system is of potential use for treatment of key components of the metabolic syndrome.
AIM: Inhibition of the acetyl-CoA carboxylase (ACC) system, consisting of the isozymes ACC1 and ACC2, may be beneficial for treatment of insulin resistance and/or obesity by interfering with de novo lipogenesis and beta-oxidation. We have evaluated effects of pharmacological inhibition of ACC by soraphen (SP) on high fat (HF) diet-induced insulin resistance in mice. METHOD: Male C57Bl6/J mice were fed control chow, a HF diet or a HF diet supplemented with SP (50 or 100 mg/kg/day). RESULTS: Body weight gain and total body fat content of SP-treated animals were significantly reduced compared with HF-fed mice. Fractional synthesis of palmitate was significantly reduced in mice treated with SP, indicative for ACC1 inhibition. Plasma beta-hydroxybutyrate levels were significantly elevated by SP, reflecting simultaneous inhibition of ACC2 activity. Mice treated with SP showed improved peripheral insulin sensitivity, as assessed by hyperinsulinaemic euglycaemic clamps. CONCLUSION: Pharmacological inhibition of the ACC system is of potential use for treatment of key components of the metabolic syndrome.
Authors: Lijun Ma; Ashis K Mondal; Mariana Murea; Neeraj K Sharma; Anke Tönjes; Kurt A Langberg; Swapan K Das; Paul W Franks; Peter Kovacs; Peter A Antinozzi; Michael Stumvoll; John S Parks; Steven C Elbein; Barry I Freedman Journal: PLoS One Date: 2011-08-26 Impact factor: 3.240
Authors: Daniel K Glatzel; Andreas Koeberle; Helmut Pein; Konstantin Löser; Anna Stark; Nelli Keksel; Oliver Werz; Rolf Müller; Iris Bischoff; Robert Fürst Journal: J Lipid Res Date: 2017-12-05 Impact factor: 5.922
Authors: Lijun Ma; Mariana Murea; James A Snipes; Alejandra Marinelarena; Jacqueline Krüger; Pamela J Hicks; Kurt A Langberg; Meredith A Bostrom; Jessica N Cooke; Daisuke Suzuki; Tetsuya Babazono; Takashi Uzu; Sydney C W Tang; Ashis K Mondal; Neeraj K Sharma; Sayuko Kobes; Peter A Antinozzi; Matthew Davis; Swapan K Das; Neda Rasouli; Philip A Kern; Nathan J Shores; Lawrence L Rudel; Matthias Blüher; Michael Stumvoll; Donald W Bowden; Shiro Maeda; John S Parks; Peter Kovacs; Robert L Hanson; Leslie J Baier; Steven C Elbein; Barry I Freedman Journal: PLoS One Date: 2013-02-27 Impact factor: 3.240